Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October, 2023

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended October 31, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:



   Ordinary Shares
     Volume Weighted
Average Price Paid
per Ordinary Share
     Highest Price Paid      Lowest Price Paid  

October 2, 2023

     54,876        178.63p        182.60p        175.60p  

October 3, 2023

     57,326        172.31p        184.40p        167.40p  

October 4, 2023

     57,432        173.38p        178.60p        166.40p  

October 5, 2023

     59,395        178.55p        183.00p        177.00p  

October 6, 2023

     59,595        182.46p        184.40p        179.80p  

October 9, 2023

     60,246        183.68p        185.00p        181.00p  

October 10, 2023

     13,692        184.65p        185.80p        183.00p  

October 11, 2023

     59,216        185.71p        189.00p        181.20p  

October 12, 2023

     58,783        184.60p        188.40p        183.00p  

October 13, 2023

     56,788        177.57p        185.60p        171.00p  

October 16, 2023

     51,734        170.91p        174.20p        168.40p  

October 17, 2023

     37,903        168.83p        170.80p        167.20p  

October 18, 2023

     45,866        171.51p        176.00p        167.80p  

October 19, 2023

     40,535        169.64p        175.80p        165.00p  

October 20, 2023

     30,962        166.20p        168.80p        162.60p  

October 23, 2023

     41,781        164.72p        167.60p        162.00p  

October 24, 2023

     35,591        166.14p        169.20p        164.60p  

October 25, 2023

     38,361        166.20p        169.40p        163.40p  

October 26, 2023

     44,415        158.31p        163.80p        155.60p  

October 27, 2023

     37,010        155.40p        158.80p        152.40p  

October 30, 2023

     43,416        157.06p        160.00p        154.40p  

October 31, 2023

     49,200        154.92         158.60         151.40   

During the month ended October 31, 2023, the Company repurchased an aggregate of 1,034,123 Ordinary Shares. As of October 31, 2023, the Company’s issued share capital was 289,468,159 shares, 15,963,277 of which were held in treasury, resulting in total voting rights in the Company of 273,504,882 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

October 2, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4919741.html

October 3, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4921189.html

October 4, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4922669.html

October 5, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4924284.html

October 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4925776.html

October 9, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4930129.html

October 10, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4932303.html

October 11, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4933862.html

October 12, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4935287.html

October 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4936760.html

October 16, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4938299.html

October 17, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4939799.html

October 18, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4941258.html

October 19, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4942641.html

October 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4944071.html

October 23, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4945524.html

October 24, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4947041.html

October 25, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4948489.html

October 26, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4949985.html

October 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4951458.html

October 30, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4952977.html

October 31, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4954599.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: November 2, 2023   By:  

/s/ Daphne Zohar

    Name:   Daphne Zohar
    Title:   Chief Executive Officer